重组人血管内皮抑制素注射液不同给药途径治疗进展期卵巢癌的效果对比  

Comparison of Therapeutic Effects of Recombinant Human Endostatin Injection on Advanced Ovarian Cancer by Different Routes of Administration

作　　者：师婕 张林燕[2] SHI Jie;ZHANG Linyan(Department of Gynecology and Oncology,Tumor Hospital of Inner Mongolia Autonomous Region,Hohhot Inner Mongolia 010000,China;Department of Gynecology,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot Inner Mongolia 010000,China)

机构地区：[1]内蒙古自治区肿瘤医院妇瘤科,内蒙古呼和浩特010000 [2]内蒙古医科大学附属医院妇科,内蒙古呼和浩特010000

出　　处：《中国卫生标准管理》2019年第4期89-91,共3页China Health Standard Management

摘　　要：目的对比重组人血管内皮抑制素注射液不同给药途径在进展期卵巢癌患者中的应用效果。方法选取我院及内蒙古医科大学附属医院收治的进展期卵巢癌患者78例作为研究对象。按照随机数字表法,将其分为两组。对照组39例,以静脉滴注重组人血管内皮抑制素注射液联合紫杉醇与顺铂联合化疗方案(TP)治疗;观察组39例,以持续静脉泵注入重组人血管内皮抑制素注射液联合TP治疗,比较两组患者的治疗效果。结果观察组患者的治疗总有效率略高于对照组,但组间比较,差异无统计学意义(P> 0.05);治疗后,两组患者血清血管内皮生长因子水平均显著改善,且观察组患者的改善程度优于同期对照组,差异具有统计学意义(P <0.05)。结论进展期卵巢癌患者采用持续静脉泵注入重组人血管内皮抑制素注射液联合紫杉醇与顺铂联合化疗方案(TP)治疗治疗效果较好,有利于促使血清血管内皮生长因子水平下降。Objective To compare the effects of different routes of administration of recombinant human endostatin injection in patients with advanced ovarian cancer.Methods A total of 78 patients with advanced ovarian cancer admitted to our hospital and the Affiliated Hospital of Inner Mongolia Medical University were selected as the research objects.According to the random number table method,they were divided into two groups.In the control group,39 cases of patients were treated with intravenous drip of human endostatin injection combined with paclitaxel and cisplatin combined chemotherapy(TP).In the observation group,39 cases of patients were treated with recombinant human endostatin injection combined with TP by continuous intravenous pump,and the therapeutic effect was compared between the two groups.Results The total effective rate of the observation group was slightly higher than that of the control group,but there was no significant difference between the two groups(P>0.05).After treatment,the levels of serum vascular endothelial growth factor in the two groups were significantly improved,and the improvement degree of the observation group was better than that of the control group at the same time,the difference was statistically significant(P<0.05).Conclusion Continuous intravenous infusion of recombinant human vascular endostatin injection combined with paclitaxel and cisplatin combined chemotherapy(TP)is effective in treating advanced ovarian cancer,which is conducive to reducing the level of serum vascular endothelial growth factor.

关 键 词：重组人血管内皮抑制素注射液 紫杉醇与顺铂联合化疗方案(TP) 给药方式 进展期卵巢癌 静脉滴注 持续静脉泵注入 

分 类 号：R737[医药卫生—肿瘤]